Australia Primary Hyperoxaluria (PH) Drugs Market Report 2023 to 2030

Australia Primary Hyperoxaluria (PH) Drugs Market Analysis

$ 3999

Australia Primary Hyperoxaluria (PH) drugs market is expected to grow from $2.1 Mn in 2022 to $8.8 Mn in 2030 with a CAGR of 19% for the year 2022-2030 due to the number of clinical trials including innovative therapeutic assets being investigated at various stages of development has increased in Australia and also new approaches being developed in genetic engineering for the treatment of PH. The market is segmented by type, diagnosis, drug, treatment, and by distribution channel. Some of the key competitors in Australia's primary hyperoxaluria market are Allena Pharmaceuticals, Alnylam Pharmaceuticals, and Amarna Therapeutics.

ID: IN10AUPH362 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Parul Choudhary

Buy Now

Australia Primary Hyperoxaluria (PH) Drugs Market Executive Analysis

Australia's Primary Hyperoxaluria (PH) drugs market is expected to grow from $2.1 Mn in 2022 to $8.8 Mn in 2030 with a CAGR of 19% for the year 2022-30. The Australian government has unveiled its first budget, allocating $104.1 Bn in total to healthcare, including $30.6 Bn for senior care. A $2.9 Bn project will result in a fundamental transformation of primary healthcare in Australia. The beginning of the rollout will be supported by a $235 Mn budget from 2022 to 2023, which will include $100 Mn over two years from 2022 to 2023 for co-developing and testing cutting-edge solutions with states and territories to improve treatment pathways and direct the rollout of the urgent care program. The maximum cost of generic prescription drugs covered by the Pharmaceutical Benefits Scheme (PBS) will decrease. As on January 1, 2023, the $42.50 maximum co-payment will be cut to $30.

Primary hyperoxaluria (PH) is a set of rare inherited metabolic disorders defined by oxalate build-up in the kidneys and other organ systems. A particular enzyme that typically inhibits the accumulation of oxalate is absent from affected individuals. Due to the fact that oxalate is normally eliminated in the urine, the kidney is the primary site of excessive oxalate deposition, which can cause kidney stones, nephrocalcinosis, and in certain circumstances, end-stage renal disease. PH affects both men and women equally. It is unknown how common and how frequently these disorders occur in Australia. The true prevalence of these illnesses in the Australian population is difficult to ascertain because some instances go untreated or are incorrectly diagnosed. With primary hyperoxaluria, the drug lumasiran (Oxlumo) lowers oxalate production in both children and adults. Prescription vitamin B-6 doses may help some individuals with primary hyperoxaluria lower the oxalate levels in their urine. Oral medicines containing phosphate and citrate help to inhibit the production of calcium oxalate crystals. Other drugs, such as thiazide diuretics, may be taken into consideration depending on the other anomalies in the urine.

australia primary hyperoxaluria drugs market

Market Dynamics

Market Growth Drivers

The number of clinical trials including innovative therapeutic assets that are being investigated at various stages of development has increased in the Australia Primary Hyperoxaluria market, and these trials are anticipated to result in the introduction of new medicines. During the projection period, demand for primary hyperoxaluria treatment will increase due to advances in genetic engineering technologies. Technological advancements in gene treatments could create an alluring alternative approach for managing PH.

Market Restraints

A high number of cases that go undiagnosed or unreported as well as differential diagnoses due to a lack of awareness and understanding of the condition limits Australia's primary hyperoxaluria market growth.

Competitive Landscape

Key Players

Allena Pharmaceuticals
Alnylam Pharmaceuticals
Amarna Therapeutics
BridgeBio
Dicerna Pharmaceuticals
Inositec
Intellia Therapeutics

Healthcare Policies and Regulatory Landscape

Australia's national health insurance program, Medicare, provides financial assistance for a number of medical and allied health services. When a claim is submitted for a health or medical service, Medicare will pay a specific benefit. Medicare only pays for treatments rendered by private practitioners. Only when a patient decides to be treated as a private patient does Medicare cover services received at a public hospital.

The Australian Government Department of Health hosts the Therapeutic Goods Administration (TGA). The TGA is in charge of making sure that all therapeutic products sold in Australia are secure and suitable for their intended use. Before authorizing therapeutic products for use in Australia, the TGA evaluates them to make sure they are both safe and effective. Because of the risk-based approach used by the TGA, therapeutic goods with higher risks are subjected to a more thorough evaluation than therapeutic goods with lower risks.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Primary Hyperoxaluria Drugs Market Segmentation

By Type

ALLN-230
DCR-PHXC
ALN-GO1
Others

By Diagnosis

Molecular genetic testing for mutations in the specific genes known to cause PH confirms the diagnosis of PH which is leading the market in terms of diagnosis of primary hyperoxaluria.

Blood tests &
Urine test
Stone analysis
X-ray Examination
CT scanning& MRI
Biopsy
Molecular genetic testing

By Drug

Pyridoxine drug is expected to generate the highest revenue for the primary hyperoxaluria treatment market which increasing demand in the coming decade.

Pyridoxine
Potassium Citrate
Thiazides
Orthophosphates

By Treatment

Shock wave lithotripsy, percutaneous nephrolithotomy, and ureteroscopy treatments are leading the market in terms of treatment of primary hyperoxaluria.

Shock wave lithotripsy
Percutaneous nephrolithotomy
Ureteroscopy
Combined liver-kidney transplantation
Isolated kidney transplant
Isolated liver transplant

By Distribution Channel

The hospital pharmacies segment is anticipated to enhance the market share over the forecast period.

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.